Avidity Biosciences (RNA) Invested Capital: 2019-2025
Historic Invested Capital for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $1.9 billion.
- Avidity Biosciences' Invested Capital rose 25.47% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 25.47%. This contributed to the annual value of $1.4 billion for FY2024, which is 184.56% up from last year.
- According to the latest figures from Q3 2025, Avidity Biosciences' Invested Capital is $1.9 billion, which was up 58.16% from $1.2 billion recorded in Q2 2025.
- Over the past 5 years, Avidity Biosciences' Invested Capital peaked at $1.9 billion during Q3 2025, and registered a low of $264.5 million during Q2 2021.
- Its 3-year average for Invested Capital is $1.0 billion, with a median of $1.2 billion in 2025.
- Its Invested Capital has fluctuated over the past 5 years, first fell by 19.93% in 2021, then spiked by 190.53% in 2024.
- Over the past 5 years, Avidity Biosciences' Invested Capital (Quarterly) stood at $381.4 million in 2021, then surged by 51.55% to $578.1 million in 2022, then declined by 13.37% to $500.8 million in 2023, then soared by 184.56% to $1.4 billion in 2024, then rose by 25.47% to $1.9 billion in 2025.
- Its Invested Capital was $1.9 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.